Article
Top news of the week from Specialty Pharmacy Times.
5. First Short-Course Oral Therapy Approved for Relapsing Forms of MS
Cladribine (Mavenclad, EMD Serono) is the first oral multiple sclerosis drug to demonstrate 2 years of proven efficacy with a maximum of 20 days of treatment. Read more.
4. Gilteritinib Prolongs Survival in Patients with FLT3-Mutated AML
Gilteritinib (Xospata) was superior to standard chemotherapy in improving overall survival in patients with acute myeloid leukemia. Read more.
3. FDA Approves Novel Intravenous Immune Globulin
Immune Globulin Intravenous, Human — slra 10% Liquid (Asceniv) is indicated for use in the treatment of primary humoral immunodeficiency disease in adults and adolescents. Read more.
2. Medicaid Coverage of Recommended Lung Cancer Screenings Varies Across States
Although lung cancer screenings are covered at no cost by most insurers, state Medicaid programs are not required to offer coverage for this service. Read more.
1. A Step by Step Guide to Establishing and Maintaining a Special Center of Excellence
Specialty pharmacy can benefit from having definitive a center of excellence model that caters to respective therapies and disease states. Read more.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa